As we know today, the laboratory is informed about how to discover medical research and drugs, as well as how to intersect artificial intelligence and biotechnology. As someone passing a technological CEO of a doctor, I first witnessed to develop the technology to think about medicine and innovation to keep the pace with acceleration changes. One of the most important lessons I have learned in my trip: You can be very smart for your own good.
This may have a reflection, but when a company is set up or investing in new technologies, the smartest people often have a trap of much too much. A bright idea is not always enough. You need creativity, accept the risks and what happens in the real world.
For me, the doctor was about to understand that the mentality of CEO was not related to medical knowledge; About the installation of the correct ecosystem to educate these knowledge and convert real and transformative change. I believe that an important part of this ecosystem for my company, Owkin, a new form of a new intelligence: Biological artificial superation (BASI) to complete the masters working with us. Owkin’s agent colleagues for Pharma, Owkin’s Agentic Employee, Phara, P Phara, which is so far, so far, so far, so far, so far, so far you have to understand the full complexity of biology.
This organizes the spine of the Owki’s mission: the different generation pharma is developing a new intelligence system, which is able to decoding biological truths, create the next generation pharma aimed at discovering treatment and increase the value of the pipeline.
Can fill the remaining innovation space left by AI Pharma
While the pharmaceutical industry is increasingly focusing on a handful of blockers, he is behind many very important drugs for the future of medicine. A large number of diseases, traditional pharma remains as a traditional Pharma fight to increase the complexity of biology with new molecules and diagnostics.
Until the rare diseases, there is an innovation gap in which the AI is perfectly placed to fill the AI. AI can previously identify the outcomes of the eye and regulate the development of high and targeted treatment.
Unlike traditional pharmaceutical companies that are very confident in large-scale, high-risk projects, AI companies can work more flexible and manually managed. Once you can use smaller, more informed bets, using smaller, more informed bets to unlimited the missing concepts. This change allows the discovery of more efficient medicine, with additional benefits of solutions for the faster and more efficient medicinal discovery, non-sufficiency of Big Pharma.
Only cell lines do not go to work
Traditional biological research is based on cell lines of cell lines removed from the human body and grown in petri pots.
As we look forward to the future, there is an obsolete realization of mobile lines and other traditional research methods. In the biomedical research, once once again, they do not repeat the complexity of human biology and do not seize variability and variability in real patients.
The EU managed models are also able to move from research in cells and textures from the body and the integration of the cell lines with the integration of information (in vitro) and from research made in living animals (vivoda). This confirmation approach, which includes more than one type of data and resources, allows us to create more reliable and predictive models of human diseases.
Science is moving forward and regulation. The latest announcement of the FDA’s “more effective, human-related methods” means the final announcement of the Phase Phase plans, therapy in the human textile models can be tested in the beginning of the human texture. In cooperation with the leading academic centers, Owkin, a faster, more accurate and more accurate drug discovery, developed a patient who approached the discovery of drugs, developed a laboratory (a mini version of a human body).
The combination of clinical data, genomical concepts and the AI does not accelerate the development of new treatment, but also increases the chances of success in clinical trials.
Laboratory of the future
The lab of the future will be one to be one to be one to increase the AI in the center, improving the discovery, accuracy and efficiency. The use of real-world data will allow you to make the right decisions and get higher success rates. The traditional research process is the best of these new technologies and this is a good thing. The future of medicine will not trust only human practice, but to change the AI power and why we understand and treat.
The AI will present a transformative therapy on the exponential scale, touching the complexity of biology, which is often able to solve the traditional pharmaceutical approaches. Laboratories use the full potential of automated and advanced AI systems, the laboratories will serve as the final playground for scientists who manage the future of the drug discovery.
These dynamic laboratories will meet in Synergy, which allows you to model and simulate human biology and simulating human biology, and simulation of scientists. AI-based technology will be deciphered in clinical trials and the chances of success in clinical trials and beyond the biological examples to identify patients. This will change the way leading advanced tools to a lab environment, to a pharmaceutical discovery and disease to a sensitivity level that is in advance.
To decipher the main mechanics of the data, biology and AI’s illness and advance medical science, it will be possible to create a foundation for the future of “positive loneliness” in medicine. It can revolutionize the AI medication through an innovative ecosystem. The time to innovate now and opportunities are endless.
Thomas Clozel is the Kofounderi and CEO of Owkin.